A detailed history of Eagle Health Investments LP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Eagle Health Investments LP holds 76,256 shares of ALNY stock, worth $18.5 Million. This represents 3.98% of its overall portfolio holdings.

Number of Shares
76,256
Previous 76,256 -0.0%
Holding current value
$18.5 Million
Previous $18.5 Million 13.2%
% of portfolio
3.98%
Previous 3.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $4 Million - $6.89 Million
27,900 Added 57.7%
76,256 $18.5 Million
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $13 Million - $17.5 Million
-88,400 Reduced 64.64%
48,356 $7.23 Million
Q1 2023

May 12, 2023

SELL
$182.66 - $235.53 $3.46 Million - $4.47 Million
-18,960 Reduced 12.18%
136,756 $27.4 Million
Q4 2022

Feb 13, 2023

SELL
$185.53 - $241.31 $1.11 Million - $1.45 Million
-6,000 Reduced 3.71%
155,716 $37 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $1.71 Million - $2.86 Million
12,336 Added 8.26%
161,716 $32.4 Million
Q2 2022

Aug 11, 2022

BUY
$120.42 - $169.29 $2.18 Million - $3.07 Million
18,136 Added 13.82%
149,380 $21.8 Million
Q1 2022

May 12, 2022

BUY
$127.18 - $173.91 $2.23 Million - $3.05 Million
17,542 Added 15.43%
131,244 $21.4 Million
Q4 2021

Feb 10, 2022

BUY
$159.56 - $209.29 $3.77 Million - $4.94 Million
23,600 Added 26.19%
113,702 $19.3 Million
Q3 2021

Oct 20, 2021

SELL
$169.75 - $207.73 $3.07 Million - $3.76 Million
-18,077 Reduced 16.71%
90,102 $17 Million
Q1 2021

Apr 23, 2021

BUY
$126.83 - $175.69 $2.84 Million - $3.93 Million
22,386 Added 26.09%
108,179 $15.3 Million
Q4 2020

Feb 04, 2021

BUY
$122.97 - $147.0 $10.5 Million - $12.6 Million
85,793 New
85,793 $11.2 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Eagle Health Investments LP Portfolio

Follow Eagle Health Investments LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Health Investments LP, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Health Investments LP with notifications on news.